Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140152 · ClinicalTrials.gov registry record
Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 17
- Enrollment target
NCT01140152 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants.
The verdict
NCT01140152 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
Many patients with intestinal failure require intestinal transplantation for survival. Currently, the gold standard for diagnosing acute cellular rejection (ACR) is histological examination of endoscopic biopsies, which are taken invasively and lack sensitivity. A non-invasive method of monitoring for ACR is needed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01140152
The ClinicalTrials.gov registry entry for NCT01140152 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01140152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01140152 about?
NCT01140152 is a clinical study titled "Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction". Many patients with intestinal failure require intestinal transplantation for survival. Currently, the gold standard for diagnosing acute cellular rejection (ACR) is histological examination of endoscopic biopsies, which are taken invasively and lack sensitivity. A non-invasive method of monitoring f...
What is the current status of trial NCT01140152?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2008-07. Estimated completion is 2009-09.
Who is sponsoring clinical trial NCT01140152?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.